Releases
See all
Releases
29. February, 2024
Annual Report 2023
Cessatech A/S publishes its annual report for the fiscal year 2023, which also includes...
Releases
9. January, 2024
Cessatech 2024 major milestones and focus
Now is the time – 2024 will be an extremely busy and hopefully exciting...
Releases
4. January, 2024
Q&A session – topline data from Study 0205
Link to release: (Link to Q&A session-image)
Releases
22. December, 2023
Positive topline data from study 0205 with its lead candidate CT001 for the treatment of pain in children supporting further advancement of CT001
The study a double-blinded, randomised, placebo-controlled in adults demonstrated that CT001 was superior to...
Releases
25. October, 2023
Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children
The European Paediatric Committee (PDCO) has agreed to a 50% reduction in the number...
Facts about Children
See all
Facts
18. March, 2024
Acute pain treatment – large unmet need, paediatrics receive least…mainly due to inadequate solutions
More than 20 million children annually, alone in Europe, are subject to acute pain...
Facts
12. February, 2024
Treating children is not just like treating small adults
Giving medicine to children can’t be a one-size-fits-all approach. Their changing anatomy and...
Facts
25. August, 2023
New findings supporting CT001
Based on new findings in a 2023 meta-analysis by Fjendbo Galili et al., which...
Facts
15. March, 2022
Off-label use of medication in children continue to be the rule rather than the exception…
A systematic review of 31 studies with off-label prescription rates confirms the continued off-label...
Facts
3. March, 2022
Physical restraint of children in 79% of Scandinavian emergency departments
Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency...
Experience
Proven track-record within drug development and product launches, in Europe, US and Asia.
The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.
Team
Lead Asset
CT001 – Nasal spray
Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.
See detailsStay up to date!
Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.